MESC for Competitors

Use medical-grade UV light to make air safe. We provide coronavirus disinfection and cleaning, and offer UV lights, robots, and HVAC sanitizing systems.

Medimetrix was founded by Joseph M. Davis, Ph.D., in 1987, with the goal of facilitating business relationships between hospitals, insurers and physicians - particularly risk-based relationships. By the mid-'90s, Medimetrix had grown into the largest standalone strategic consulting practice in the country and was providing services to all sectors of the healthcare industry. Medimetrix operated out of several cities and was headquartered in Cleveland, Ohio. In the late 90s, Medimetrix began selling off most of its practices and narrowed its focus to strategic engagements primarily for health systems and insurers. During this same period, Medimetrix developed The Spirit of Women® program, which is used today in more than 100 health systems nationwide and compromise over 40% of the U.S. healthcare market, as well as the HeartCaring program, which creates partnerships to connect consumers with designated hospitals and clinicians committed to gender-sensitive practice for prevention, early diagnosis and treatment of cardiovascular diseases and conditions. In 2005, Medimetrix began narrowing its practice primarily to existing relationships and currently only occasionally takes on a new client, typically an organization lacking meaningful history at an executive level. In 2007, Medimetrix created a new parent company, Spirit Health Group®, which also serves as the umbrella for The Spirit of Women® Hospital Network, The HeartCaring® Hospital Network, Spirit Health MediaTM and Spirit Health PartnershipsTM. In 2010, Medimetrix developed Medimetrix Solutions Exchange which has evolved into an effective marketing channel for hospitals and health systems, strengthened by their website, MX.com, the first online marketplace for hospitals to discover free & licensed Solutions, white papers, industry news, and more.

APEX is a patient-driven pharmaceutical company focused on optimizing the standard of mental health care with psilocybin by bringing data supported, clinically evaluated drugs to market for depression and anxiety in PTSD. Our strategy is focused on developing pharmaceutical products through a phased clinical program evaluating safety and efficacy across multiple indications, alongside a robust early access program. APEX has two GMP Certified drug assets. APEX-52 is microdose synthetic psilocybin for clinical evaluation, currently in active phase 2b trials, and APEX-25 is the company’s macro dose drug asset, developed for in-clinic dosing with assisted psychotherapy. APEX recently launched North America’s first take-home psilocybin trial, and received approval for the world’s largest psilocybin clinical trial to-date both evaluating APEX-52 in the treatment of anxiety and depression in diagnosed PTSD. APEX is driven by an experienced and passionate leadership team from the Veteran community, healthcare, drug policy and emerging sectors who want to make a difference and disrupt the $380+ billion global mental health market. Find out more at apexlabs.com